Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT04719585 |
Other study ID # |
KC20MISI0531 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
January 2021 |
Est. completion date |
December 2022 |
Study information
Verified date |
January 2021 |
Source |
The Catholic University of Korea |
Contact |
Yong In, MD, PhD |
Phone |
82-10-9044-5228 |
Email |
iy1000[@]catholic.ac.kr |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) has recently been reported to be effective
in controlling pain in persistent chronic pain caused by joint surgery and arthritis.
However, opioids are important drugs that still play a pivotal role in pain control after
surgery. In this study, we want to investigate the difference of the result among patients
who undego total knee arthroplasty (TKA), of the result of pain control after TKA from SNRI
administration of duloxetine and opioid in two groups. We designed a randomized controlled
study (RCT) for the effect of post-TKA pain control to determine whether SNRI is effective in
controlling post-TKA pain compared to Opioid, and whether there is a difference in side
effects.
Description:
For patients undergoing TKA for osteoarthritis of the knee joint, pain control will be
performed using the same pain control technique (pain control using NSAID) until discharge (1
week after surgery) after surgery. By evaluating the Visual Analogue Scale (VAS), which is
known as the patient's pain criterion, the study will be conducted only on patients whose
score is more severe than 4 points. Among these subjects, only patients who agreed to the
study will be assigned to the group taking duloxetine and the group taking opioids with the
same probability according to the randomization table for one week after surgery, that is,
upon discharge. In our hospital, almost all patients with total knee arthroplasty are
discharged one week after surgery, except for special cases such as morbidity of systemic
diseases such as cardiopulmonary dysfunction or acute infection after surgery.
Among the co-researchers, one researcher who is in charge of only patient assignment is
selected, and the person in charge creates a randomization table through computer generated
randomization. During the assignment process, the assignee will not know in advance the next
assignment group, and the randomization table is kept in secret. The assignee does not
intervene in any other process of this study, and participates only in the task of selecting
the assigned group using random checks. The evaluation is evaluated by an evaluator who is
not aware of the patient allocation according to the randomization table among researchers
participating in the clinical study. Such a study plan will be fully explained to the patient
in the process of seeking consent for the study before discharge, as it is recorded in detail
in the subject description, and only patients who have obtained this consent will be the
subject of the study.
This criterion is established because both duloxetine and opioid are not used for all
patients after surgery, but for additional pain control after surgery. Prior to discharge,
the drug is prescribed for a total of 6 weeks by dividing the duloxetine-administered group
and the opioid-administering group, respectively. In general, if duloxetine is not taken for
more than 10 weeks, the frequency of discontinuation syndrome that can occur after
discontinuation is remarkably low, so the administration period of 6 weeks was set as the
administration period. The follow-up periods for out-patient clinic are 2 weeks, 6 weeks, 3
months, 6 months, and 1 year after the TKA surgery. During the follow-up period, NSAIDs will
be prescribed the same in both groups.
As an additional rescue medication, 650 mg of acetaminophen will be allowed to use up to 2g
per day.
Before surgery, 1 week after surgery, 2 weeks, 6 weeks, 3 months, 6 months, 1 year The degree
of pain will be measured using the VAS pain scale, WOMAC pain scale, Brief pain inventory
(BPI), Intermittent and Constant Osteoarthritis The pain (ICOAP) score is used to measure
additional pain scales in various ways. In addition, SF-36 will be measured before surgery,
at 6 weeks, 3 months, 6 months, and 1 year after surgery.